Sébium Kerato+

• Keratolytic and comedolytic action (-41%** of acne volume, after 2 days ⁽¹⁾ ; lasting results : -53% lesions after 56 days ⁽⁶⁾)
• Reduction of pimples and marks (-36.2%** of pigment spots and marks surface ⁽¹⁾ ; -60% residual marks after 56 days ⁽²⁾ )
• Anti-imperfection effect: decrease in inflammatory elements (-21%)*⁽²⁾
• Provides an immediate skin comfort ⁽²⁾
• 8h hydration (+31%** of hydration level) ⁽³⁾ 
• Improves quality of life (-57% of acne impact on well-being) ⁽⁶⁾

Very good cutaneous tolerance ⁽⁴⁾ – Non-comedogenic ⁽²⁾ – Gel-cream texture – Easy to apply – Penetrates quickly – Does not leave an oily and sticky finish ⁽²⁾ – Recommended in routine with Sebium Gel Moussant Actif ⁽⁵⁾

Clinically tested on patients with mild or moderate acne and oily skin

*p<0.05, student t-test, after 28 days / ** p<0.001 paired student t-test, after 28 days

(1) Evaluation and tolerance assessment of Sebium Kerato+ by clinical scorage, non-comparative and intra-individual study - 30 patients (aged 19 - 39 years old) with mild or moderate acne with twice daily application. Brazil. 2022
(2) Evaluation of tolerance, comedogenic potential of Sebium Kerato+ - 33 patients (aged 18 - 42 years old) with combination to oily and prone to acne skin. Tunisia. 2021
(3) Evaluation of moisturizing effect of Sébium Kerato+ - 10 volunteers (aged 22 -64 years old) with dry or moderately hydrated skin on the forearms with only one application. France. 2021
(4) Evaluation of the immediate tolerance on acne-prone skin of Sebium Kerato+ - 20 patients (aged 19 – 45 years old) with combination to oily skin and with acne-prone skin on the face with only one application. France. 2021
(5) Evaluation of tolerance, comedogenic potential and efficacy of Sebium Kerato+ - 32 patients (aged 18 - 36 years old) with combination or greasy skin or with acne-prone skin after twice daily application of Sebium Gel Moussant Actif and Kerato+.

(6) Evaluation of tolerance, comedogenic potential, patients' quality of life and long-term efficacy of Sébium Kerato+ - 257 patients (aged 12 - 48 years old) with mild to moderate acne with twice-daily application. Europe. 2022-2023.

> CLINICAL RESULTS
As soon as after 2 days of using twice daily Sebium Kerato+, it significantly reduced:

• Size of pigments spots (-19.6%*) ⁽¹⁾
• Acne volume (-18.9%***) ⁽¹⁾

and significantly increases:

• Skin homogeneity (+23.1%*) ⁽¹⁾
  
  

After 28 days of using twice daily Sebium Kerato+, a significant decrease of -11.1%* in acne severity was observed in comparison to D0 (1). The study also shows a significant decrease in:

• Number of retention lesions (-11.7%) ⁽¹⁾
• Number of inflammatory lesions (-31.8%**) ⁽¹⁾
• Number of acne residual blemishes (-6.8%*) ⁽¹⁾
• Oiliness (-31%***) ⁽¹⁾
• Size of pigment spots (-36.2%***) ⁽¹⁾
• Acne volume (-41.1%***) ⁽¹⁾
• Skin texture (-7.0%**) ⁽¹⁾
• Skin thickness (-11.2%*) ⁽¹⁾

and a significant increase in:

• Skin homogeneity (+60%**) ⁽¹⁾

After 10 days of twice daily application, Sebium Kerato+ allows also to significantly accelerate the cellular renewal by 28%.*** ⁽²⁾

It significantly increases the level of hydration of 31%*** and can be considered as a very good moisturizer. ⁽⁴⁾

Sebium Kerato+ is non-comedogenic and non-acneigenic. ⁽⁵⁾

In combination with Sebium Gel Moussant Actif, Sebium routine significantly decreased the number of inflammatory lesions of 23.2%**** and retentional lesions of 33.9%.****⁽⁶⁾

LONG LASTING RESULTS

After 56 days of using twice daily Sebium Kerato+, a significant decrease of -41.%* in acne severity was observed in comparison to D0 ⁽⁷⁾. 

More than half of the subjects presented either a significant improvement of their acne or disappearance of lesions ⁽⁷⁾

The study also shows a significant decrease in:

• Number of retentional lesions (-51%***) ⁽⁷⁾
• Number of inflammatory lesions (-57%***) ⁽⁷⁾
• Number of residual marks (-60%***) ⁽⁷⁾
• Seborrhea intensity (-44%***) ⁽⁷⁾
• Acne impact on well-being (-57%***) ⁽⁷⁾

TOLERANCE
Sébium Kerato+ demonstrated a very good cutaneous tolerance. ⁽³⁾

Sébium Kerato+ was very well tolerated for 98% of the subjects. ⁽⁷⁾

*p<0.05 **/ **p<0.01 / ***p<0.001, paired t-test, after 2 or 28 days
**** p<0.0001, paired t-test or Wilcoxon test, after 28 days

> PATIENTS FEEDBACKS
After 28 days of use, for more than 83% of subjects, Sebium Kerato+ does not dry out the skin, reduces marks of acne and improves the skin’s state.⁽¹⁾
Skin immediately feels comfortable and hydrated for 100% of subject .⁽⁵⁾
In combination with Sebium Gel Moussant Actif, pimples are visibly reduced for 97% of subjects.⁽⁶⁾

After 56 days of use, 78% of the subjects had their quality of life has improved.⁽⁷⁾

During the study, 100% of the subjects were compliant with the product use. ⁽⁷⁾

(1) Evaluation and tolerance assessment of Sebium Kerato+ by clinical scorage, non-comparative and intra-individual study - 30 patients (aged 19 - 39 years old) with mild or moderate acne with twice daily application. Brazil. 2022
(2) Evaluation of the efficacy on the cellular renewal of Sebium Kerato+ by image analysis - 16 patients (aged 36 - 65 years old) with dry to very dry skin. France. 2021
(3) Self-assessment of immediate tolerance of Sebium Kerato+ - 20 patients (aged 19 - 45 years old) with combination to oily skin and with acne-prone skin on the face after only one application. France. 2021
(4) Evaluation of moisturizing effect of Sébium Kerato+ - 10 volunteers (aged 22 -64 years old) with dry or moderately hydrated skin on the forearms with only one application. France. 2021
(5) Evaluation of tolerance, comedogenic potential of Sebium Kerato+ - 33 patients (aged 18 - 42 years old) with combination to oily and prone to acne skin. Tunisia. 2021
(6) Evaluation of tolerance, comedogenic potential and efficacy of Sebium Kerato+ - 32 volunteers (aged 18 - 36 years old) with combination or greasy skin or with acne-prone skin after twice daily application of Sebium Gel Moussant Actif and Kerato+.

(7) Evaluation of tolerance, comedogenic potential, patients' quality of life and long-term efficacy of Sébium Kerato+ - 257 patients (aged 12 - 48 years old) with mild to moderate acne with twice-daily application. Europe. 2022-2023.